• Home
  • Study Details

Clinical trial of alvelestat in alpha-1 antitrypsin patients

The purpose of the study is to test how a new drug called Alvelestat affects the signs of lung damage caused by Alpha-1 antitrypsin deficiency (AATD). AATD is a rare genetic condition that can cause Chronic Obstructive Pulmonary Disease (COPD.)

Age & Gender

  • 25 years ~ 80 years
  • Male, Female


North Carolina (Statewide)

What will be asked of you

1-2 Screening, 1 eye exam, 1 CAT scan, 1 randomization, 9 follow-up visits, 3 phone visits


$50-$100 per study visit. Total compensation $830

In-person visits : 14
Phone or online visits : 3
Total length of participation : Up to 6 months (3 months of medication)

Looking for Specific Volunteers

Able to participate:

  • Confirmed diagnosis of alpha-1 antitrypsin deficiency

Not eligible if:

  • Pregnant or plan to become pregnant
  • History of cirrhosis, hepatitis or HIV
  • History of heart failure

Contact the Team

Visit Location

100% Remote (online, phone, text)

Additional Study Information

Principal Investigator

Brad Drummond

Study Topics

Genetics and Genetic Disorders
Lungs and Breathing

IRB Number


logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.


  • This email address is being protected from spambots. You need JavaScript enabled to view it.